[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655597":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":25,"armGroups":26,"interventions":31,"overallOfficials":21,"centralContacts":36,"locations":42,"responsibleParty":58,"collaborators":21,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":21,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":21,"enrollmentInfo":70,"targetDuration":21,"studyType":73,"phases":21,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":80,"whyStopped":21,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Acibadem University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Parkinson Neuropsychometric Dementia Assessment (PANDA) Total Score","Cognitive performance will be assessed using the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. The PANDA is a brief cognitive screening instrument specifically developed for Parkinson's disease and includes tasks assessing learning and memory, verbal fluency, visuospatial processing, working memory, and delayed recall.\n\nThe PANDA total score ranges from 0 to 30, with higher scores indicating better cognitive performance. The psychometric properties of the Turkish version, including internal consistency, test-retest reliability, and construct validity, will be evaluated.","[Time Frame: Baseline (at the time of PANDA administration)]",[14,18],{"measure":15,"description":16,"timeFrame":17},"Montreal Cognitive Assessment (MoCA) Total Score","Global cognitive performance will be assessed using the Montreal Cognitive Assessment (MoCA), a widely used cognitive screening tool that evaluates multiple cognitive domains, including attention, executive functions, memory, language, visuospatial abilities, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.\n\nMoCA scores will be used to evaluate the convergent construct validity of the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA).","[Time Frame: Baseline (at the time of cognitive assessment)]",{"measure":19,"description":20,"timeFrame":17},"Mini-Mental State Examination (MMSE) Total Score","General cognitive status will also be assessed using the Mini-Mental State Examination (MMSE), which evaluates orientation, registration, attention and calculation, recall, language, and visuospatial abilities. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.\n\nMMSE scores will be examined in relation to PANDA scores to further assess the convergent construct validity of the Turkish version of the PANDA.",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","CROSS_SECTIONAL","The study population will consist of individuals with clinically diagnosed Parkinson's disease (Hoehn and Yahr stage 1-3), aged between 40 and 85 years, with adequate cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department. The study population represents ambulatory individuals with mild to moderate disease severity suitable for comprehensive biopsychosocial assessment.",[27],{"label":28,"type":21,"description":21,"interventionNames":29},"Parkinson's Disease",[30],"Other: Parkinson Neuropsychometric Dementia Assessment",[32],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":21},"Parkinson Neuropsychometric Dementia Assessment","Participants will complete the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA) as part of the psychometric evaluation process. The PANDA will be administered according to standardized instructions to assess cognitive performance in individuals with Parkinson's disease. To evaluate test-retest reliability, the Turkish PANDA will be re-administered to a subgroup of participants after a predefined interval under similar conditions. No therapeutic intervention will be provided as part of this methodological validation study.",[28],[37],{"name":38,"role":39,"phone":40,"phoneExt":21,"email":41},"Nuray Alaca Alaca, Prof. Dr","CONTACT","05324251290","nuraygeceralaca@gmail.com",[43],{"facility":5,"status":21,"city":44,"state":45,"zip":46,"country":47,"countryCode":21,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Istanbul","Turkey","+90","Turkey (Türkiye)",{"type":49,"coordinates":50},"Point",[51,52],28.94966,41.01384,{"lat":52,"lon":51},[55],{"name":56,"role":39,"phone":40,"phoneExt":21,"email":57},"Nuray ALACA","nuray.alaca@acibadem.edu.tr",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Nuray Alaca","Prof. Dr","100655597","turkish-validity-and-reliability-of-the-parkinsons-disease-neuropsychometric-dementia-assessment-questionnaire-in-individuals-with-parkinsons-disease-100655597",false,"NCT07815964","Turkish Validity and Reliability of the Parkinson's Disease Neuropsychometric Dementia Assessment Questionnaire in Individuals With Parkinson's Disease","\\*\\*Inclusion Criteria:\\*\\*\n\n* Clinical diagnosis of Parkinson's disease\n* Hoehn and Yahr stage 1-3\n* Age between 40 and 85 years\n* Mini-Mental State Examination score ≥ 24\n* Sufficient cognitive and communication ability to complete the assessments\n* Attendance at the Movement Disorders Outpatient Clinic of the Neurology Department\n* Willingness to participate in the study and provide written informed consent\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Presence of a major psychiatric disorder, such as major depressive disorder or a psychotic disorder\n* Diagnosis of advanced dementia\n* Presence of an uncontrolled systemic chronic disease, such as uncontrolled diabetes mellitus or hypertension\n* Presence of a severe cardiovascular or respiratory condition\n* Presence of an additional orthopedic or neurological condition that may affect assessment performance\n* Severe visual or hearing impairment that may interfere with the assessments\n* Inability to cooperate adequately during the assessments","ALL","40 Years",{"count":71,"type":72},100,"ESTIMATED","OBSERVATIONAL","The aim of this study is to examine the validity and reliability of the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. This cross-sectional methodological study will evaluate the psychometric properties of the Turkish PANDA, including internal consistency, test-retest reliability, and construct validity, in order to provide a valid and reliable instrument for the assessment of cognitive impairment and dementia-related cognitive changes in Turkish-speaking individuals with Parkinson's disease.",[76],"PARKINSON DISEASE (Disorder)",[78,79],"Parkinson's disease","Rehabilitation","NOT_YET_RECRUITING","2026-09-11",{"date":83,"type":84},"2026-09-14","ACTUAL",{"date":86,"type":72},"2026-10-01",{"date":88,"type":72},"2027-07-01",{"name":5,"class":6},1]